Ivanhoe Capital (IVAN) Shareholders Approve SES Deal
by Marlena Haddad on 2022-02-01 at 5:47pm

Ivanhoe Capital (NYSE:IVAN) announced this afternoon that its shareholders have approved its combination with EV battery-maker SES in a special meeting held this morning.

The SPAC announced a preliminary approval of the business combination yesterday, however, Ivanhoe disclosed in an 8-K filing that 22,455,850 shares were presented for redemption, representing 81.362% of the SPACs trust. As a result, there will be approximately $51.45 million remaining in the trust account following redemptions.

But, in late October, the SPAC entered into an additional PIPE subscription agreement which increased the total PIPE size to $275 million thanks to the additional $75 million subscription at $10.00 per share from strategic investor Honda. Together with SES’ existing cash, the company is expected to have about $480 million on its balance sheet at close.

The upsized PIPE included $275 million common stock offering, which will close on Thursday, and includes multiple industry leading OEM’s and strategic partners, along with premier financial investors. The PIPE investors include: Honda Motor Co. Ltd., General Motors, Hyundai Motor Company, Geely Holding Group, Kia Corporation, SAIC Motor, Koch Strategic Platforms, LG Technology Ventures, Foxconn, Vertex Ventures, Fidelity Investments Canada ULC (certain funds), and Franklin Templeton. SES investors also include SK Inc., Temasek, Tianqi Lithium, and Applied Materials.

The business combination is expected to close on Thursday, February 3, and the common stock and warrants of the combined company, which will be renamed “SES AI Corporation,” are expected to commence trading on the New York Stock Exchange on Friday, February 4, under the new ticker symbols, “SES” and “SES WS”, respectively.

Ivanhoe Capital and SES initially announced their $2.6 billion deal on July 13. Singapore-based SES is developing a hybrid lithium-metal rechargeable battery for electric vehicles with full production expected to launch in 2025.


ADVISORS

  • Goldman Sachs & Co. LLC is serving as exclusive financial advisor to SES.
  • White & Case LLP is serving as legal advisor to SES.
  • Morgan Stanley & Co. LLC is serving as sole placement agent on the PIPE offering and as exclusive financial advisor to Ivanhoe.
  • Kirkland & Ellis LLP is serving as legal advisor to Ivanhoe.
  • ICR, LLC is serving as communications advisor for SES.
Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved